NRx Pharmaceuticals (NRXP) to Release Earnings on Monday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to be announcing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $1.33 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $19.43 million. On average, analysts expect NRx Pharmaceuticals to post $-0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $3.58 on Monday. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The stock has a 50 day moving average price of $3.90 and a two-hundred day moving average price of $2.92. The stock has a market capitalization of $129.70 million, a P/E ratio of -3.28 and a beta of 2.18.

Wall Street Analysts Forecast Growth

NRXP has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, April 27th. BTIG Research cut their target price on shares of NRx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research report on Friday. Finally, Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of NRXP. Geode Capital Management LLC increased its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after acquiring an additional 37,598 shares during the period. Vanguard Group Inc. raised its stake in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the last quarter. Two Sigma Investments LP boosted its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the period. Commonwealth Equity Services LLC bought a new stake in NRx Pharmaceuticals in the 4th quarter valued at $994,000. Finally, State Street Corp grew its position in NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.